Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design.
暂无分享,去创建一个
S. Trudel | P. Richardson | N. Callander | A. Nooka | B. Holkova | M. Minnema | N. V. D. van de Donk | K. Weisel | B. Kremer | G. Ferron-Brady | D. Routledge | K. Song | E. Im | C. Ahlers | H. Quach | I. Gupta | S. Paul | Shinta Cheng | N. Jackson | L. Smith | P. R. Otero | Nahi Hareth | Maria Brouch | Rocío Montes de Oca | Geraldine Ferron-Brady
[1] S. Trudel,et al. DREAMM-8: A Phase III Study of the Efficacy and Safety of Belantamab Mafodotin with Pomalidomide and Dexamethasone (B-Pd) Vs Pomalidomide Plus Bortezomib and Dexamethasone (PVd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) , 2020 .
[2] A. Nooka,et al. DREAMM-6: Safety, Tolerability and Clinical Activity of Belantamab Mafodotin (Belamaf) in Combination with Bortezomib/Dexamethasone (BorDex) in Relapsed/Refractory Multiple Myeloma (RRMM) , 2020 .
[3] M. Dimopoulos,et al. DREAMM-7: A Phase III Study of the Efficacy and Safety of Belantamab Mafodotin (Belamaf) with Bortezomib, and Dexamethasone (B-Vd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) , 2020 .
[4] S. Lonial,et al. Single-agent belantamab mafodotin for relapsed/refractory multiple myeloma: analysis of the lyophilised presentation cohort from the pivotal DREAMM-2 study , 2020, Blood Cancer Journal.
[5] M. Bi,et al. Abstract 2220: Non-clinical tumor models reveal broad combination potential of ICOS agonist antibodies , 2020 .
[6] A. Jakubowiak,et al. Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody–Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study , 2020, Ophthalmology and Therapy.
[7] Y. Tai,et al. BCMA-Targeting Therapy: Driving a New Era of Immunotherapy in Multiple Myeloma , 2020, Cancers.
[8] Yu Chen,et al. Looking for the Optimal PD-1/PD-L1 Inhibitor in Cancer Treatment: A Comparison in Basic Structure, Function, and Clinical Practice , 2020, Frontiers in Immunology.
[9] P. Richardson,et al. DREAMM-5 platform trial: Belantamab mafodotin in combination with novel agents in patients with relapsed/refractory multiple myeloma (RRMM). , 2020 .
[10] T. Myklebust,et al. Incidence and survival of multiple myeloma: a population‐based study of 10 524 patients diagnosed 1982–2017 , 2020, British journal of haematology.
[11] A. Chari,et al. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches , 2020, Leukemia.
[12] S. Lonial,et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. , 2019, The Lancet. Oncology.
[13] M. Boccadoro,et al. Pursuing a Curative Approach in Multiple Myeloma: A Review of New Therapeutic Strategies , 2019, Cancers.
[14] J. A. Krueger,et al. Synergistic Activity of Belantamab Mafodotin (anti-BCMA immuno-conjugate) with PF-03084014 (gamma-secretase inhibitor) in Bcma-Expressing Cancer Cell Lines , 2019, Blood.
[15] D. Siegel,et al. Pembrolizumab combined with lenalidomide and low‐dose dexamethasone for relapsed or refractory multiple myeloma: phase I KEYNOTE‐023 study , 2019, British journal of haematology.
[16] I. Melero,et al. Dendritic cells in cancer immunology and immunotherapy , 2019, Nature Reviews Immunology.
[17] Herman Goossens,et al. Adaptive platform trials: definition, design, conduct and reporting considerations , 2019, Nature Reviews Drug Discovery.
[18] Jason J. Z. Liao,et al. Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial. , 2019, The Lancet. Haematology.
[19] Yingqi Hua,et al. Immunogenic cell death in cancer therapy: Present and emerging inducers , 2019, Journal of cellular and molecular medicine.
[20] R. Sullivan,et al. Preliminary safety, efficacy, and pharmacokinetic/pharmacodynamic characterization from GARNET, a phase I/II clinical trial of the anti–PD-1 monoclonal antibody, TSR-042, in patients with recurrent or advanced MSI-h and MSS endometrial cancer , 2019, Gynecologic Oncology.
[21] O. Kepp,et al. PF558 THE ANTI-BCMA ANTIBODY-DRUG CONJUGATE GSK2857916 DRIVES IMMUNOGENIC CELL DEATH AND IMMUNE-MEDIATED ANTI-TUMOR RESPONSES, AND IN COMBINATION WITH AN OX40 AGONIST POTENTIATES IN VIVO ACTIVITY , 2019, HemaSphere.
[22] Karl Broich,et al. Master protocols in clinical trials: a universal Swiss Army knife? , 2019, The Lancet. Oncology.
[23] M. Parmar,et al. Mind the gap? The platform trial as a working environment , 2019, Trials.
[24] V. Bragulat,et al. Phase I/II, open-label, 2-arm study to evaluate safety, tolerability, and clinical activity of GSK2857916 in combination with 2 standard-of-care (SoC) regimens in relapsed/refractory multiple myeloma: (DREAMM 6). , 2019, Journal of Clinical Oncology.
[25] S. Trudel,et al. Antibody–drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study , 2019, Blood Cancer Journal.
[26] R. Vij,et al. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy , 2019, Leukemia.
[27] S. Trudel,et al. Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial. , 2018, The Lancet. Oncology.
[28] M. Dimopoulos,et al. Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting , 2018, Blood Cancer Journal.
[29] D. Olive,et al. Preclinical evaluation of a non-depleting, first-in-class humanized IgG4 agonist anti-ICOS antibody. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.
[30] P. Richardson,et al. How I treat the young patient with multiple myeloma. , 2018, Blood.
[31] M. Dimopoulos,et al. Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 4‐year follow‐up and analysis of relative progression‐free survival from the randomized ELOQUENT‐2 trial , 2018, Cancer.
[32] K. Anderson,et al. Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy , 2018, Front. Immunol..
[33] A. Hoos,et al. The promise and challenges of immune agonist antibody development in cancer , 2018, Nature Reviews Drug Discovery.
[34] A. Gural,et al. Daratumumab resistance is frequent in advanced‐stage multiple myeloma patients irrespective of CD38 expression and is related to dismal prognosis , 2018, European journal of haematology.
[35] P. Richardson,et al. CD38 antibodies in multiple myeloma: back to the future. , 2018, Blood.
[36] H. Lokhorst,et al. Current and New Therapeutic Strategies for Relapsed and Refractory Multiple Myeloma: An Update , 2017, Drugs.
[37] A. Lesokhin,et al. Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed/refractory multiple myeloma. , 2017, Blood.
[38] J. Woodcock,et al. Master Protocols to Study Multiple Therapies, Multiple Diseases, or Both. , 2017, The New England journal of medicine.
[39] T. Golde,et al. γ‐Secretase inhibitors in cancer clinical trials are pharmacologically and functionally distinct , 2017, EMBO molecular medicine.
[40] P. Sonneveld,et al. How have evolutions in strategies for the treatment of relapsed/refractory multiple myeloma translated into improved outcomes for patients? , 2017, Critical reviews in oncology/hematology.
[41] P. Meltzer,et al. Clinical Activity of the γ-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors (Aggressive Fibromatosis). , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[42] J. Wolchok,et al. Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity , 2017, Nature Communications.
[43] T. Spektor,et al. Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients , 2016, Haematologica.
[44] S. Lonial,et al. New Strategies in Multiple Myeloma: Immunotherapy as a Novel Approach to Treat Patients with Multiple Myeloma , 2016, Clinical Cancer Research.
[45] K. Yong,et al. Evaluation of B cell maturation antigen as a target for antibody drug conjugate mediated cytotoxicity in multiple myeloma , 2016, British journal of haematology.
[46] A. Palumbo,et al. Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma. , 2016, The New England journal of medicine.
[47] H. Goldschmidt,et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. , 2016, The Lancet. Oncology.
[48] M. Delforge,et al. Multiple myeloma: patient outcomes in real‐world practice , 2016, British journal of haematology.
[49] Sandra A Mitchell,et al. Patient-Reported Outcomes in Cancer Clinical Trials: Measuring Symptomatic Adverse Events With the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). , 2016, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.
[50] U. Mellqvist,et al. Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group , 2016, Leukemia.
[51] S. Berry,et al. Efficiencies of platform clinical trials: A vision of the future , 2016, Clinical trials.
[52] M. Mcnamara,et al. OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal , 2015, Front. Oncol..
[53] Anthony O'Hagan,et al. Robust meta‐analytic‐predictive priors in clinical trials with historical control information , 2014, Biometrics.
[54] A. Jimeno,et al. A Phase I, Dose-Finding Study in Patients with Advanced Solid Malignancies of the Oral γ-Secretase Inhibitor PF-03084014 , 2014, Clinical Cancer Research.
[55] N. Munshi,et al. Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. , 2014, Blood.
[56] T. Luetkens,et al. Coinhibitory molecule PD-1 as a potential target for the immunotherapy of multiple myeloma , 2014, Leukemia.
[57] B. Fox,et al. OX40 is a potent immune-stimulating target in late-stage cancer patients. , 2013, Cancer research.
[58] S. Vincent Rajkumar,et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients , 2013, Leukemia.
[59] J. Crowley,et al. Serum B‐cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival , 2012, British journal of haematology.
[60] H. Goldschmidt,et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study , 2012, Leukemia.
[61] D. Munn,et al. Blockade of Programmed Death-1 Pathway Rescues the Effector Function of Tumor-Infiltrating T Cells and Enhances the Antitumor Efficacy of Lentivector Immunization , 2010, The Journal of Immunology.
[62] Yuan Ji,et al. A modified toxicity probability interval method for dose-finding trials. , 2010, Clinical trials.
[63] M. Caligiuri,et al. The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. , 2010, Blood.
[64] S. Rosenberg,et al. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. , 2009, Blood.
[65] T. So,et al. The significance of OX40 and OX40L to T‐cell biology and immune disease , 2009, Immunological reviews.
[66] M. Dimopoulos,et al. Treatment of relapsed/refractory multiple myeloma. , 2009, Seminars in hematology.
[67] Michael Branson,et al. Critical aspects of the Bayesian approach to phase I cancer trials , 2008, Statistics in medicine.
[68] Yoshimasa Tanaka,et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer , 2007, Proceedings of the National Academy of Sciences.
[69] Wei Zhu,et al. An agonist human ICOS monoclonal antibody that induces T cell activation and inhibits proliferation of a myeloma cell line. , 2004, Hybridoma and hybridomics.
[70] M. Nishimura,et al. B7-H1 Expression on Non-Small Cell Lung Cancer Cells and Its Relationship with Tumor-Infiltrating Lymphocytes and Their PD-1 Expression , 2004, Clinical Cancer Research.
[71] R. Bram,et al. BCMA Is Essential for the Survival of Long-lived Bone Marrow Plasma Cells , 2004, The Journal of experimental medicine.
[72] T. Horan,et al. Potent activity of soluble B7RP‐1‐Fc in therapy of murine tumors in syngeneic hosts , 2003, International journal of cancer.
[73] R. Schiffman,et al. Reliability and validity of the Ocular Surface Disease Index. , 2000, Archives of ophthalmology.
[74] A. Barclay,et al. Characterization of the MRC OX40 antigen of activated CD4 positive T lymphocytes‐‐a molecule related to nerve growth factor receptor. , 1990, The EMBO journal.
[75] S. Mboup,et al. Minerva Access is the Institutional Repository of The University of Melbourne , 2021 .
[76] R. Herbst,et al. Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer. , 2016, JAMA oncology.
[77] S. Lonial,et al. New Targets and New Agents in High-Risk Multiple Myeloma. , 2016, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.
[78] O. Cope,et al. Multiple myeloma. , 1948, The New England journal of medicine.